Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling

Abstract Omaveloxolone is a nuclear factor (erythroid‐derived 2)‐like 2 activator approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years, with a recommended dosage of 150 mg orally once daily on an empty stomach. The effect of the US...

Full description

Bibliographic Details

Published in:	CPT: Pharmacometrics & Systems Pharmacology
Main Authors:	Xavier J. H. Pepin, Scott M. Hynes, Hamim Zahir, Deborah Walker, Lois Q. Semmens, Sandra Suarez‐Sharp
Format:	Article
Language:	English
Published:	Wiley 2024-10-01
Online Access:	https://doi.org/10.1002/psp4.13221